Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Paller AS, Siegfried EC, Marron SE, Clark M, Harris N, Kosa K, Qin S, Whalley D, Chao J, Bansal A, Chuang CC, Wang Z. Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis. J Eur Acad Dermatol Venereol. 2024 Jun 29. doi: 10.1111/jdv.20199

Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870

Augustin M, Mcbride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047

Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, Mcbride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094

Luciano JV, D’Amico F, Feliu-Soler A, McCracken LM, Aguado J, Penarrubia-Maria MT, Knapp M, Serrano-Blanco A, Garcia-Campayo J. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain. 2017 Jul;18(7):868-80. doi: 10.1016/j.jpain.2017.03.001

Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, Mcbride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478

Slade GD, Bair E, By K, Mulkey F, Baraian C, Rothwell R, Reynolds ME, Miller V, Gonzalez Y, Gordon S, Ribeiro-Dasilva M, Lim PF, Greenspan JD, Dubner R, Fillingim RB, Diatchenko L, Maixner W, Dampier D, Knott C, Ohrbach R. Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study. J Pain. 2011 Nov;12(11 Suppl):T12-26.

Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. 2010 Nov 1;11(11):1230-9.

Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol. 2010 Jun;15(2):151-7.

Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008 Sep;9(9):792-805.

Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, Sharma U. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. J Pain. 2008 Jun;136(3):419-31.

Evans C, Katz N, Simon L, Bombardier C, West C, Robbins J, Copley-Merriman K, Coombs J. Development and preliminary validation of a responder index for patients with chronic low back pain. J Pain. 2006 Apr;7(4 (Supplement)):S84. doi: 10.1016/j.jpain.2006.01.341

McKennas SP, Whalley D, deProst Y, Staab D, Huels J, Paul CF, vanAssche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 Mar 1;20(3):248-54.

Jensen MP, Martin SA, Cheung R. The Meaning of pain relief in a clinical trial. J Pain. 2005 Jun 1;6:400-6.

Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.

Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P. Measuring quality of life in lupus: development of the SLEQoL. Poster presented at the First EADV International Spring Symposium; February 2003. [abstract] J Eur Acad Dermatol Venereol. 2003 Mar; 17(Suppl 1):58.

Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.

Dubrey SW, Gnanasakthy A, Stein WK, Song JG, Hardman T, Hynd J, Noble MI. Enoximone in chronic stable angina: a double-blind placebo-controlled cross-over trial. J Cardiovasc Pharmacol. 1994 Apr;23(4):532-8.